Submission of Notice of Extra Ordinary General Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has called an EGM on January 9, 2026 at 3:30 PM via video conferencing to seek shareholder approval for two items. The first is a preferential allotment of 25,00,000 equity shares at Rs. 60 each (face value Rs. 10, premium Rs. 50), raising up to Rs. 15 crore in total. Shares are proposed to be issued to 40 allottees, including 1 promoter group entity (Pavani Vupparapalli – 3,25,000 shares) and 39 non-promoter individuals, with the largest non-promoter allottee being Venkataramana Reddy Mallela (3,30,000 shares). The second item is the confirmation of Ms. Sridevi Belide (DIN: 10455373) as Non-Executive Non-Independent Director, appointed by the board w.e.f. October 23, 2025. The relevant date for pricing is December 10, 2025, and the e-voting window runs from January 6 to January 8, 2026 (cut-off date January 2, 2026).
If approved, the Rs. 15 crore preferential issue will dilute existing shareholders' equity by issuing new shares to promoter group and select non-promoter investors. The shares will be locked-in per SEBI ICDR rules. Director appointment is routine but expands the board. Outcome of the EGM vote on January 9, 2026 will determine whether the capital raise goes through.